News
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026
PORTLAND, Maine, May 14, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops and markets products to improve calf health and productivity, today announced its unaudited financial...
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2026
Conference Call Scheduled for Friday, May 15, 2026 at 9:00 AM ETPORTLAND, Maine, May 07, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops and markets products to improve calf...
ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors
PORTLAND, Maine, April 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops and markets products to improve calf health and productivity, announced that Dr. Gilles Guillemette...
ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results
PORTLAND, Maine, April 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced...
ImmuCell Appoints Former Elanco Animal Health Board Member Kathy Turner to Board
PORTLAND, Maine, March 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products to improve calf health and productivity, today announced that...
ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2025
PORTLAND, Maine, March 04, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, today announced its unaudited...
ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2025
Conference Call Scheduled for Thursday, March 5, 2026 at 9:00 AM ETPORTLAND, Maine, Feb. 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health company that develops, manufactures and markets products that...
ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025
PORTLAND, Maine, Jan. 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, today announced preliminary,...
ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus
Conference Call Scheduled for Friday, January 9, 2026 at 9:00 AM ETPORTLAND, Maine, Jan. 07, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health company that develops, manufactures and markets products that...
ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain®
PORTLAND, Maine, Dec. 24, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell"), an animal health company that develops, manufactures and markets products that improve cattle health and productivity today announced that it received an Incomplete...